Research programme: protein targeting therapeutics - Primary Peptides/Yabao PharmaceuticalsAlternative Names: K13; PP 001; PP 002; PP 003
Latest Information Update: 15 Oct 2015
At a glance
- Originator Primary Peptides
- Developer Primary Peptides; Yabao Pharmaceutical Group
- Mechanism of Action Alpha-synuclein modulators; Cell death modulators; JNK mitogen-activated protein kinase modulators; PTEN inhibitors; TDP-43 protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Myocardial infarction; Neurodegenerative disorders; Neuroprotection; Parkinson's disease; Stroke